Annekathryn Goodman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Cervical Neoplasms | 12 | 2023 | 2039 | 1.660 |
Why?
|
Vulvar Neoplasms | 6 | 2022 | 266 | 1.500 |
Why?
|
Endometrial Neoplasms | 12 | 2021 | 1381 | 1.370 |
Why?
|
Genital Neoplasms, Female | 7 | 2022 | 534 | 1.030 |
Why?
|
Ovarian Neoplasms | 13 | 2024 | 4903 | 0.990 |
Why?
|
Gynecologic Surgical Procedures | 5 | 2015 | 287 | 0.900 |
Why?
|
Social Justice | 2 | 2022 | 484 | 0.860 |
Why?
|
Ovarian Cysts | 1 | 2023 | 107 | 0.800 |
Why?
|
Vaginal Smears | 4 | 2021 | 505 | 0.780 |
Why?
|
Prisons | 2 | 2023 | 178 | 0.750 |
Why?
|
Uterine Neoplasms | 7 | 2015 | 1424 | 0.690 |
Why?
|
Early Detection of Cancer | 6 | 2023 | 3235 | 0.660 |
Why?
|
Cystadenocarcinoma, Serous | 5 | 2024 | 480 | 0.620 |
Why?
|
Papillomavirus Infections | 5 | 2021 | 1639 | 0.610 |
Why?
|
Lymph Node Excision | 10 | 2022 | 1267 | 0.600 |
Why?
|
Uterine Cervical Dysplasia | 3 | 2015 | 391 | 0.580 |
Why?
|
Sentinel Lymph Node Biopsy | 3 | 2022 | 734 | 0.560 |
Why?
|
Minors | 1 | 2015 | 59 | 0.480 |
Why?
|
Carcinoma, Endometrioid | 5 | 2021 | 275 | 0.470 |
Why?
|
Papillomaviridae | 5 | 2021 | 1139 | 0.460 |
Why?
|
Dissent and Disputes | 1 | 2015 | 150 | 0.460 |
Why?
|
Postmenopause | 3 | 2021 | 2517 | 0.450 |
Why?
|
Disaster Medicine | 1 | 2014 | 75 | 0.410 |
Why?
|
Medical Oncology | 3 | 2015 | 2340 | 0.390 |
Why?
|
Adenocarcinoma, Clear Cell | 3 | 2017 | 218 | 0.380 |
Why?
|
Vulvar Diseases | 1 | 2011 | 64 | 0.370 |
Why?
|
Earthquakes | 1 | 2014 | 192 | 0.370 |
Why?
|
Neoplasm Staging | 19 | 2024 | 11218 | 0.350 |
Why?
|
Oocytes | 1 | 2015 | 1168 | 0.350 |
Why?
|
Cryopreservation | 1 | 2015 | 727 | 0.350 |
Why?
|
Ulcer | 1 | 2011 | 203 | 0.340 |
Why?
|
Developing Countries | 2 | 2013 | 2912 | 0.340 |
Why?
|
Gynecology | 2 | 2015 | 534 | 0.330 |
Why?
|
Splenectomy | 1 | 2011 | 390 | 0.330 |
Why?
|
Infertility, Female | 1 | 2015 | 763 | 0.330 |
Why?
|
Mixed Tumor, Mullerian | 3 | 2004 | 55 | 0.320 |
Why?
|
Equipment and Supplies | 1 | 2012 | 273 | 0.320 |
Why?
|
Health Care Rationing | 1 | 2012 | 435 | 0.300 |
Why?
|
Counseling | 1 | 2015 | 1550 | 0.280 |
Why?
|
Mass Screening | 5 | 2023 | 5454 | 0.280 |
Why?
|
Obstetrics | 1 | 2014 | 679 | 0.270 |
Why?
|
Hysterectomy | 7 | 2021 | 863 | 0.270 |
Why?
|
Uterine Hemorrhage | 2 | 2021 | 235 | 0.260 |
Why?
|
Lymphatic Metastasis | 6 | 2022 | 2901 | 0.260 |
Why?
|
Female | 58 | 2024 | 396532 | 0.260 |
Why?
|
Health Services Needs and Demand | 1 | 2014 | 1404 | 0.250 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2022 | 4050 | 0.250 |
Why?
|
Lymph Nodes | 6 | 2022 | 3468 | 0.240 |
Why?
|
Women's Health | 1 | 2014 | 2081 | 0.230 |
Why?
|
Pharmaceutical Preparations | 1 | 2012 | 1086 | 0.220 |
Why?
|
False Negative Reactions | 2 | 2016 | 570 | 0.210 |
Why?
|
Cervix Uteri | 2 | 2013 | 575 | 0.210 |
Why?
|
Adenosarcoma | 1 | 2003 | 36 | 0.210 |
Why?
|
Carcinosarcoma | 2 | 2013 | 108 | 0.200 |
Why?
|
Referral and Consultation | 1 | 2015 | 3618 | 0.190 |
Why?
|
Parents | 1 | 2015 | 3592 | 0.190 |
Why?
|
Humans | 59 | 2024 | 766812 | 0.180 |
Why?
|
Survival Rate | 10 | 2019 | 12826 | 0.180 |
Why?
|
Education, Medical, Graduate | 1 | 2012 | 2418 | 0.170 |
Why?
|
Leiomyosarcoma | 1 | 2004 | 426 | 0.170 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 3692 | 0.170 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2014 | 4056 | 0.170 |
Why?
|
Patient Selection | 1 | 2012 | 4252 | 0.170 |
Why?
|
Ki-67 Antigen | 1 | 2021 | 630 | 0.160 |
Why?
|
Coloring Agents | 1 | 2021 | 565 | 0.160 |
Why?
|
Laparoscopy | 4 | 2017 | 2038 | 0.150 |
Why?
|
Hospitals | 1 | 2012 | 3885 | 0.150 |
Why?
|
Doxorubicin | 3 | 2005 | 2229 | 0.150 |
Why?
|
Cytodiagnosis | 1 | 2021 | 450 | 0.150 |
Why?
|
Physicians | 1 | 2015 | 4591 | 0.140 |
Why?
|
Pelvis | 3 | 2016 | 737 | 0.140 |
Why?
|
Retrospective Studies | 21 | 2024 | 81657 | 0.140 |
Why?
|
CA-125 Antigen | 2 | 2008 | 282 | 0.130 |
Why?
|
Adenocarcinoma, Mucinous | 2 | 2017 | 523 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2019 | 3552 | 0.120 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2015 | 1788 | 0.120 |
Why?
|
Carcinoma, Papillary | 2 | 2012 | 791 | 0.120 |
Why?
|
Adenocarcinoma | 2 | 2013 | 6359 | 0.120 |
Why?
|
Aged | 29 | 2024 | 171344 | 0.120 |
Why?
|
Disease-Free Survival | 5 | 2016 | 6853 | 0.120 |
Why?
|
Intraoperative Care | 2 | 2016 | 768 | 0.120 |
Why?
|
Menopause | 1 | 2022 | 1656 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2021 | 980 | 0.110 |
Why?
|
Aged, 80 and over | 16 | 2019 | 59548 | 0.110 |
Why?
|
Intraoperative Period | 1 | 2015 | 512 | 0.110 |
Why?
|
Incidence | 3 | 2021 | 21527 | 0.110 |
Why?
|
Erythrocyte Transfusion | 1 | 2019 | 574 | 0.110 |
Why?
|
Health Planning Guidelines | 1 | 2014 | 151 | 0.110 |
Why?
|
Acetic Acid | 1 | 2013 | 58 | 0.110 |
Why?
|
Myometrium | 1 | 2014 | 174 | 0.110 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2017 | 488 | 0.110 |
Why?
|
Middle Aged | 31 | 2024 | 223267 | 0.100 |
Why?
|
Personal Autonomy | 1 | 2015 | 316 | 0.100 |
Why?
|
Mobile Health Units | 1 | 2014 | 93 | 0.100 |
Why?
|
Combined Modality Therapy | 8 | 2017 | 8540 | 0.100 |
Why?
|
Colposcopy | 2 | 2023 | 151 | 0.100 |
Why?
|
SEER Program | 5 | 2016 | 1444 | 0.100 |
Why?
|
Standard of Care | 1 | 2016 | 569 | 0.100 |
Why?
|
Parenteral Nutrition, Total | 1 | 2013 | 304 | 0.100 |
Why?
|
Lichen Sclerosus et Atrophicus | 1 | 2011 | 26 | 0.100 |
Why?
|
Endometrium | 1 | 2013 | 406 | 0.090 |
Why?
|
Ethics, Medical | 1 | 2015 | 785 | 0.090 |
Why?
|
Gastrostomy | 1 | 2013 | 325 | 0.090 |
Why?
|
Follow-Up Studies | 4 | 2023 | 39312 | 0.080 |
Why?
|
Brazil | 1 | 2014 | 1250 | 0.080 |
Why?
|
Public Policy | 1 | 2014 | 551 | 0.080 |
Why?
|
Ultrasonography | 1 | 2023 | 5990 | 0.080 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 195 | 0.080 |
Why?
|
Tumor Virus Infections | 2 | 2004 | 438 | 0.080 |
Why?
|
Surgical Wound Infection | 1 | 2019 | 1547 | 0.080 |
Why?
|
Choice Behavior | 1 | 2015 | 846 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2014 | 968 | 0.080 |
Why?
|
Adult | 19 | 2024 | 223305 | 0.080 |
Why?
|
Intestinal Obstruction | 1 | 2013 | 433 | 0.080 |
Why?
|
Informed Consent | 1 | 2015 | 1010 | 0.080 |
Why?
|
Aorta | 1 | 2016 | 2043 | 0.080 |
Why?
|
Intraoperative Complications | 1 | 2014 | 1171 | 0.070 |
Why?
|
Prognosis | 8 | 2020 | 29959 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2020 | 9407 | 0.070 |
Why?
|
Social Stigma | 1 | 2014 | 788 | 0.070 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2014 | 790 | 0.070 |
Why?
|
Fellowships and Scholarships | 2 | 2012 | 1134 | 0.070 |
Why?
|
Hemangiosarcoma | 1 | 2008 | 214 | 0.060 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2024 | 1536 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 1883 | 0.060 |
Why?
|
Ultrasonography, Prenatal | 1 | 2014 | 1772 | 0.060 |
Why?
|
Endometriosis | 1 | 2013 | 868 | 0.060 |
Why?
|
Pulmonary Embolism | 1 | 2019 | 2596 | 0.060 |
Why?
|
DNA, Viral | 2 | 2003 | 2201 | 0.060 |
Why?
|
Length of Stay | 3 | 2017 | 6491 | 0.060 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2004 | 39 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2014 | 2007 | 0.060 |
Why?
|
Aging | 1 | 2023 | 8728 | 0.060 |
Why?
|
Radiotherapy | 3 | 2016 | 1497 | 0.060 |
Why?
|
DNA Probes, HPV | 1 | 2003 | 21 | 0.060 |
Why?
|
Social Support | 1 | 2014 | 2191 | 0.060 |
Why?
|
Haiti | 1 | 2005 | 553 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2882 | 0.050 |
Why?
|
Biopsy | 2 | 2013 | 6779 | 0.050 |
Why?
|
Risk | 2 | 2014 | 9602 | 0.050 |
Why?
|
Pregnancy Outcome | 1 | 2014 | 2971 | 0.050 |
Why?
|
Antineoplastic Agents | 3 | 2015 | 13644 | 0.050 |
Why?
|
Religion | 1 | 2005 | 376 | 0.050 |
Why?
|
Preoperative Care | 1 | 2011 | 2253 | 0.050 |
Why?
|
Proportional Hazards Models | 4 | 2022 | 12536 | 0.050 |
Why?
|
Laparotomy | 2 | 2017 | 459 | 0.050 |
Why?
|
Mortality | 1 | 2013 | 2908 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 11876 | 0.050 |
Why?
|
Culture | 1 | 2005 | 622 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2017 | 1012 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2020 | 65286 | 0.050 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2003 | 329 | 0.050 |
Why?
|
Endometrial Hyperplasia | 1 | 2021 | 102 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2004 | 617 | 0.040 |
Why?
|
Paclitaxel | 2 | 2005 | 1728 | 0.040 |
Why?
|
Genome, Viral | 1 | 2003 | 674 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6514 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 13090 | 0.040 |
Why?
|
Blood Loss, Surgical | 2 | 2014 | 642 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2019 | 15831 | 0.040 |
Why?
|
Nitriles | 1 | 2003 | 981 | 0.040 |
Why?
|
Triazoles | 1 | 2003 | 902 | 0.040 |
Why?
|
Prevalence | 1 | 2015 | 15835 | 0.040 |
Why?
|
Cohort Studies | 5 | 2022 | 41706 | 0.040 |
Why?
|
Palliative Care | 1 | 2013 | 3640 | 0.040 |
Why?
|
Pregnancy | 2 | 2023 | 30236 | 0.040 |
Why?
|
Survival Analysis | 3 | 2017 | 10101 | 0.040 |
Why?
|
Peritoneal Neoplasms | 1 | 2003 | 706 | 0.040 |
Why?
|
Propensity Score | 1 | 2024 | 1972 | 0.030 |
Why?
|
Neoadjuvant Therapy | 2 | 2019 | 2902 | 0.030 |
Why?
|
United States | 5 | 2017 | 72945 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 784 | 0.030 |
Why?
|
Logistic Models | 3 | 2014 | 13276 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2004 | 2334 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2016 | 4892 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 12985 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2014 | 26387 | 0.030 |
Why?
|
Platinum Compounds | 1 | 2013 | 94 | 0.030 |
Why?
|
Boston | 1 | 2005 | 9346 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2014 | 406 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2020 | 2028 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2005 | 3230 | 0.020 |
Why?
|
Perioperative Care | 1 | 2019 | 1043 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2020 | 2703 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12064 | 0.020 |
Why?
|
Young Adult | 2 | 2015 | 59939 | 0.020 |
Why?
|
Quality of Life | 2 | 2022 | 13476 | 0.020 |
Why?
|
Premenopause | 1 | 2013 | 1039 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 904 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2013 | 1838 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1902 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2005 | 5367 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2869 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2846 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 2011 | 602 | 0.020 |
Why?
|
Adolescent | 1 | 2015 | 88902 | 0.020 |
Why?
|
Time Factors | 3 | 2013 | 40149 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2011 | 1186 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2921 | 0.020 |
Why?
|
Ovariectomy | 1 | 2008 | 612 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3610 | 0.020 |
Why?
|
Filgrastim | 1 | 2005 | 132 | 0.010 |
Why?
|
Robotics | 1 | 2011 | 807 | 0.010 |
Why?
|
Risk Factors | 3 | 2012 | 74889 | 0.010 |
Why?
|
Topotecan | 1 | 2004 | 131 | 0.010 |
Why?
|
Fertility | 1 | 2009 | 770 | 0.010 |
Why?
|
Heart Rate | 1 | 2014 | 4207 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2005 | 633 | 0.010 |
Why?
|
Carboplatin | 1 | 2005 | 790 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2013 | 1880 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8352 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18397 | 0.010 |
Why?
|
Odds Ratio | 1 | 2012 | 9661 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2004 | 2228 | 0.010 |
Why?
|
Blood Pressure | 1 | 2014 | 8533 | 0.010 |
Why?
|
Receptors, Progesterone | 1 | 2003 | 1159 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2014 | 5330 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 54872 | 0.010 |
Why?
|
Brachytherapy | 1 | 2005 | 1221 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20710 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 4853 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 22248 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2012 | 3837 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2003 | 2252 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2005 | 6507 | 0.010 |
Why?
|
Body Mass Index | 1 | 2011 | 13050 | 0.010 |
Why?
|
Risk Assessment | 1 | 2014 | 24299 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2003 | 2598 | 0.010 |
Why?
|
Pilot Projects | 1 | 2005 | 8728 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2004 | 11062 | 0.010 |
Why?
|
Mutation | 1 | 2013 | 30214 | 0.000 |
Why?
|